Racial Disparities in the Optimal Delivery of Chronic Kidney Disease Care

Department of Medicine, Johns Hopkins School of Medicine, 2024 East Monument Street, Suite 2-600, Baltimore, MD 21205, USA.
Medical Clinics of North America (Impact Factor: 2.61). 06/2005; 89(3):475-88. DOI: 10.1016/j.mcna.2004.11.004
Source: PubMed


This article provides evidence that the current and growing burden of CKD in racial and ethnic minority populations is likely to be multifactorial involving the interplay of biologic, clinical, social, and behavioral determinants. To eliminate these disparities, crafting successful solutions requires more attention to the constellation of contributing factors not only by specialists, primary care physicians, and other health care providers involved in CKD care, but also clinical and behavioral scientists, payers of health care, and patients.

Download full-text


Available from: Michal Melamed, Dec 25, 2013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To examine the trends in the incidence of end-stage renal disease in Wisconsin from 1982 to 2003. De-identified incidence data for this study were supplied by the Renal Network of the Upper Midwest (Region 11). We examined trends in the incidence of end-stage renal disease by age, race, gender, and primary diagnosis from 1982 to 2003. The incidence of end-stage renal disease increased more than 3-fold from 1982 to 2003. This increase was especially striking in persons with diabetes and hypertension, as well as among those aged > or = 75 years. The increase in the incidence of end-stage renal disease was also apparent among all racial groups and both genders. The continued increase in the incidence of end-stage renal disease in Wisconsin may result from a number of factors, such as an unintended consequence of better chronic disease management, which may predispose older individuals to end-stage renal disease. Resources aimed at decreasing the incidence of end-stage renal disease are needed to prevent unnecessary health care costs and negative health outcomes, including loss of life.
    WMJ: official publication of the State Medical Society of Wisconsin 12/2005; 104(8):66-71.
  • Source

    Clinical Journal of the American Society of Nephrology 10/2006; 1(5):905-6. DOI:10.2215/CJN.02660706 · 4.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Depression has been identified as a complicating comorbid diagnosis in a variety of medical conditions, including end-stage renal disease (ESRD). Despite this, the psychological health of hemodialysis patients is understudied. The purpose of this paper is to review the research and issues involved in the assessment of depression and its sequelae in ESRD. Accurate estimation of the prevalence of depression in the ESRD population has been difficult due to the use of different definitions of depression and varied assessment techniques, the overlap of depressive symptomatology with symptoms of uremia, and the confounding effects of medications. We suggest that depressive affect is a more important construct to study than diagnosis of depression syndromes per se in patients with chronic kidney disease. The Beck Depression Inventory is a reasonable measure of depressive affect in the ESRD population, if a higher than usual cutoff score is used or if its somatic components are omitted. Several pathways link depression and ESRD, and are probably bidirectional. As such, treatment of depressive affect could impact medical as well as psychological outcomes. The need for treatment intervention trials is great. Limited evidence regarding the safety and efficacy of treatment of hemodialysis patients with selective serotonin reuptake inhibitors is available, and cognitive behavioral therapy holds promise as an intervention for depression in this complex medical population.
    Nature Clinical Practice Nephrology 01/2007; 2(12):678-87. DOI:10.1038/ncpneph0359 · 6.08 Impact Factor
Show more